FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2211-2221 May 26, 2005 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Physicians prescribe drugs on the basis of the characteristics of the medications and on the probability that reliable and reproducible clinical effects will result. However, differences in drug response among patients are common, often leading to challenges in optimizing a dosage regimen for an individual patient. Most major drugs are effective in only 25 to 60 percent of patients,¹ and more than 2 million cases of adverse drug reactions occur annually in the United States, including 100,000 deaths.² Such variability in drug response among patients is multifactorial, including environmental, genetic, and disease determinants that affect the disposition (absorption, distribution, metabolism, . . . [Full Text of this Article]

Cytochrome P-450

Drug Metabolism by CYP3A

Drug Interactions Involving Inhibition of CYP3A

Drug Interactions Involving Induction of CYP3A

Genetic Polymorphisms in Drug Metabolism

Drug Metabolism by CYP2D6

Drug Metabolism by CYP2C19

Drug Metabolism by CYP2C9

Future Perspectives

Source Information

From the Department of Pharmacology, Vanderbilt University, Nashville.

Address reprint requests to Dr. Wilkinson at the Department of Pharmacology, Vanderbilt University, 542 Robinson Research Bldg., Nashville, TN 37232-6600, or at grant.wilkinson@vanderbilt.edu.

Related Letters:

Drug Metabolism and Variability
Bjarnason N. H., Wilkinson G. R.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:955-956, Sep 1, 2005. Correspondence

This article has been cited by other articles:

• Roberts, P. J., Rollins, K. D., Kashuba, A. D. M., Paine, M. F., Nelsen, A. C., Williams, E. E., Moran, C., Lamba, J. K., Schuetz, E. G., Hawke, R. L. (2008). The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans. Drug Metab. Dispos. 36: 1465-1469 [Abstract] [Full Text]  
• Lam, S., Partovi, N., Ting, L. S., Ensom, M. H. (2008). Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact or Fiction?. The Annals of Pharmacotherapy 42: 1037-1047 [Abstract] [Full Text]  
• Patrono, C., Baigent, C., Hirsh, J., Roth, G. (2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 199S-233S [Abstract] [Full Text]  
• Kereiakes, D. J., Gurbel, P. A. (2008). Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention. J Am Coll Cardiol Intv 1: 111-121 [Abstract] [Full Text]  
• Isoherranen, N., Ludington, S. R., Givens, R. C., Lamba, J. K., Pusek, S. N., Dees, E. C., Blough, D. K., Iwanaga, K., Hawke, R. L., Schuetz, E. G., Watkins, P. B., Thummel, K. E., Paine, M. F. (2008). The Influence of CYP3A5 Expression on the Extent of Hepatic CYP3A Inhibition Is Substrate-Dependent: An in Vitro-in Vivo Evaluation. Drug Metab. Dispos. 36: 146-154 [Abstract] [Full Text]  
• Wink, J., Veering, B. Th., Kruit, M., Burm, A. G. L., Huledal, G. A. I., Ekstrom, G. Y., Stienstra, R., van Kleef, J. W. (2008). The Effect of a Long Term Epidural Infusion of Ropivacaine on CYP2D6 Activity. Anesth. Analg. 106: 143-146 [Abstract] [Full Text]  
• Rodriguez-Antona, C., Leskela, S., Zajac, M., Cuadros, M., Alves, J., Moneo, M. V., Martin, C., Cigudosa, J. C., Carnero, A., Robledo, M., Benitez, J., Martinez-Delgado, B. (2007). Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood 110: 3345-3351 [Abstract] [Full Text]  
• Washington, C., Hou, S. Y. E., Hughes, N. C., Campanella, C., Berner, B. (2007). Ciprofloxacin Prolonged-Release Tablets Do Not Affect Warfarin Pharmacokinetics and Pharmacodynamics. J Clin Pharmacol 47: 1320-1326 [Abstract] [Full Text]  
• Mathijssen, R. H.J., de Jong, F. A., Loos, W. J., van der Bol, J. M., Verweij, J., Sparreboom, A. (2007). Flat-Fixed Dosing Versus Body Surface Area Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference?. The Oncologist 12: 913-923 [Abstract] [Full Text]  
• Ben-Zaken Cohen, S., Pare, P. D., Man, S. F. P., Sin, D. D. (2007). The Growing Burden of Chronic Obstructive Pulmonary Disease and Lung Cancer in Women: Examining Sex Differences in Cigarette Smoke Metabolism. Am. J. Respir. Crit. Care Med. 176: 113-120 [Abstract] [Full Text]  
• Daly, T. M., Dumaual, C. M., Miao, X., Farmen, M. W., Njau, R. K., Fu, D.-J., Bauer, N. L., Close, S., Watanabe, N., Bruckner, C., Hardenbol, P., Hockett, R. D. (2007). Multiplex Assay for Comprehensive Genotyping of Genes Involved in Drug Metabolism, Excretion, and Transport. Clin. Chem. 53: 1222-1230 [Abstract] [Full Text]  
• Moy, B., Goss, P. E. (2007). Lapatinib-Associated Toxicity and Practical Management Recommendations. The Oncologist 12: 756-765 [Abstract] [Full Text]  
• Amal Al Omari, , Murry, D. J. (2007). Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance. Journal of Pharmacy Practice 20: 206-218 [Abstract]  
• Goodin, S. (2007). Oral chemotherapeutic agents: Understanding mechanisms of action and drug interactions. Am J Health Syst Pharm 64: S15-S24 [Abstract] [Full Text]  
• Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M.-A., Lassalle, R., Marit, G., Reiffers, J., Begaud, B., Moore, N., Molimard, M., Mahon, F.-X. (2007). Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109: 3496-3499 [Abstract] [Full Text]  
• Kim, Y. M., Yoo, S. H., Kang, R. Y., Kim, M. J., Bae, Y. Y., Lee, Y. K., Jeon, S. J., Chon, K. J., Shin, S. M., Kim, S. G., Park, K. H., Son, I. J. (2007). Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am J Health Syst Pharm 64: 166-175 [Abstract] [Full Text]  
• Fitzgerald, D. J., Maree, A. (2007). Aspirin and Clopidogrel Resistance. ASH Education Book 2007: 114-120 [Abstract] [Full Text]  
• American Academy of Pediatrics, , American Academy of Pediatric Dentistry, , Cote, C. J., Wilson, S., the Work Group on Sedation, (2006). Guidelines for Monitoring and Management of Pediatric Patients During and After Sedation for Diagnostic and Therapeutic Procedures: An Update. Pediatrics 118: 2587-2602 [Abstract] [Full Text]  
• Fulco, P. P., Vora, U. B, Bearman, G. M. (2006). Acid Suppressive Therapy and the Effects on Protease Inhibitors. The Annals of Pharmacotherapy 40: 1974-1983 [Abstract] [Full Text]  
• Hulot, J.-S., Bura, A., Villard, E., Azizi, M., Remones, V., Goyenvalle, C., Aiach, M., Lechat, P., Gaussem, P. (2006). Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108: 2244-2247 [Abstract] [Full Text]  
• Geist, M. J.P., Egerer, G., Burhenne, J., Mikus, G. (2006). Safety of Voriconazole in a Patient with CYP2C9*2/CYP2C9*2 Genotype.. Antimicrob. Agents Chemother. 50: 3227-3228 [Full Text]  
• Nolin, T. D., Appiah, K., Kendrick, S. A., Le, P., McMonagle, E., Himmelfarb, J. (2006). Hemodialysis Acutely Improves Hepatic CYP3A4 Metabolic Activity. J. Am. Soc. Nephrol. 17: 2363-2367 [Abstract] [Full Text]  
• Caramori, G., Papi, A., Mutgi, A., Hammersley, J., Kuramochi, Y., Morita, T., Osawa, R., Andraws, R., Johnston, S. L., Nieman, R. B., the Telithromycin, Chlamydophila, and Asthma Trial, (2006). Telithromycin in acute exacerbations of asthma.. NEJM 355: 96-97 [Full Text]  
• Paine, M. F, Widmer, W. W, Hart, H. L, Pusek, S. N, Beavers, K. L, Criss, A. B, Brown, S. S, Thomas, B. F, Watkins, P. B (2006). A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am. J. Clin. Nutr. 83: 1097-1105 [Abstract] [Full Text]  
• Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., Zeldin, D. C. (2006). THE HUMAN INTESTINAL CYTOCHROME P450 "PIE". Drug Metab. Dispos. 34: 880-886 [Abstract] [Full Text]  
• Sparreboom, A., Figg, W. D. (2006). Identifying sources of interindividual pharmacokinetic variability with population modeling.. Clin. Cancer Res. 12: 1951-1953 [Full Text]  
• Grube, M., Meyer zu Schwabedissen, H. E.U., Prager;, D., Haney, J., Moritz, K.-U., Meissner, K., Rosskopf, D., Eckel, L., Bohm, M., Jedlitschky, G., Kroemer, H. K. (2006). Uptake of Cardiovascular Drugs Into the Human Heart: Expression, Regulation, and Function of the Carnitine Transporter OCTN2 (SLC22A5). Circulation 113: 1114-1122 [Abstract] [Full Text]  
• Nelson, M. H, Dolder, C. R (2006). Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors. The Annals of Pharmacotherapy 40: 261-269 [Abstract] [Full Text]  
• McGriff-Lee, N. J, Csako, G., Chen, J. T, Dang, D. K, Rosenfeld, K. G, Cannon, R. O, Macklin, L R., Wesley, R. A, Anticoagulation Working Group, (2005). Search for Predictors of Nontherapeutic INR Results with Warfarin Therapy. The Annals of Pharmacotherapy 39: 1996-2002 [Abstract] [Full Text]  
• Holmes, F. A., Liticker, J. D. (2005). Pharmacogenomics of Tamoxifen in a Nutshell--And Who Broke the Nutcracker?. J Oncol Pract 1: 155-159 [Full Text]  
• Sadee, W., Dai, Z. (2005). Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 14: R207-R214 [Abstract] [Full Text]  
• Bjarnason, N. H., Wilkinson, G. R. (2005). Drug Metabolism and Variability. NEJM 353: 955-956 [Full Text]  
• Perrine, S. P. (2005). Fetal Globin Induction--Can It Cure {beta} Thalassemia?. ASH Education Book 2005: 38-44 [Abstract] [Full Text]